Table 1

Baseline characteristics of the treatment groups*

Treatment groupContinuous budesonideBudesonide/placeboTotal
No. of patients5858116
 Age group 5–6 years old252954
 Age group 7–8 years old192443
 Age group 9–10 years old14519
Age (years)7.0 (5–10)6.7 (5–10)
Male (%)34 (59)38 (66)72 (62)
Skin prick test positive (n)354176
Asthma symptom score (0–10)1.5 (0–5.5)1.7 (0–4.5)
 Age group 5–6 years old1.5 (0–5.8)1.7 (0–4.5)
 Age group 7–8 years old1.7 (0–5.5)2.0 (0–4.5)
 Age group 9–10 years old1.3 (0–3.6)2.0 (0–4.1)
Reliever medication (dose/24 h)1.0 (0–5.0)1.2 (0–5.4)
 Age group 5–6 years old1.1 (0–5.0)1.2 (0–5.4)
 Age group 7–8 years old0.7 (0–3.8)0.9 (0–3.3)
 Age group 9–10 years old1.4 (0–5.0)2.0 (0.9–3.4)
FEV1, % predicted value (range)90 (50–119)85 (52–120)
 Age group 5–6 years old91 (67–119)84 (52–106)
 Age group 7–8 years old93 (50–116)89 (61–120)
 Age group 9–10 years old84 (60–98)80 (66–98)
  • * Values are means with ranges in parentheses, unless otherwise stated.

  • Data from run-in period.

  • FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow rate.